MA41785A - Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques - Google Patents
Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiquesInfo
- Publication number
- MA41785A MA41785A MA041785A MA41785A MA41785A MA 41785 A MA41785 A MA 41785A MA 041785 A MA041785 A MA 041785A MA 41785 A MA41785 A MA 41785A MA 41785 A MA41785 A MA 41785A
- Authority
- MA
- Morocco
- Prior art keywords
- fumarates
- compositions
- treatment
- methods
- intravenous administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562136431P | 2015-03-20 | 2015-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41785A true MA41785A (fr) | 2018-01-23 |
Family
ID=55702079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041785A MA41785A (fr) | 2015-03-20 | 2016-03-17 | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
Country Status (15)
Country | Link |
---|---|
US (1) | US20180289655A1 (fr) |
EP (1) | EP3270895A2 (fr) |
JP (1) | JP2018508559A (fr) |
KR (1) | KR20170138437A (fr) |
CN (1) | CN107666905A (fr) |
AR (1) | AR104029A1 (fr) |
AU (1) | AU2016235743A1 (fr) |
CA (1) | CA2979544A1 (fr) |
EA (1) | EA201792076A1 (fr) |
HK (1) | HK1244680A1 (fr) |
IL (1) | IL254576A0 (fr) |
MA (1) | MA41785A (fr) |
MX (1) | MX2017012239A (fr) |
TW (1) | TW201642847A (fr) |
WO (1) | WO2016153957A2 (fr) |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
BRPI0410805A (pt) * | 2003-09-09 | 2006-06-27 | Fumapharm Ag | uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma |
CA2478458A1 (fr) | 2004-08-20 | 2006-02-20 | Michael Panzara | Traitement de la sclerose en plaques pediatrique |
PL1799196T3 (pl) * | 2004-10-08 | 2016-12-30 | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego | |
WO2007042035A2 (fr) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Therapie de combinaison pour le traitement d'un trouble auto-immun et/ou inflammatoire et de conditions associees |
US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
EP2139467B1 (fr) * | 2007-02-08 | 2016-09-21 | Biogen MA Inc. | Neuroprotection dans des maladies démyélinisantes |
EP2680008A1 (fr) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Essais de criblage de Nrf2 et procédés et compositions correspondants |
EP2671891A3 (fr) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Inhibition d'ang-2 pour traiter la sclérose en plaques |
DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
CA2760133A1 (fr) | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Traitement de la neurodegenerescence et de la neuroinflammation |
RS54551B1 (en) | 2010-02-12 | 2016-06-30 | Biogen Ma Inc. | NEUROPROTECTION IN DEMYELINING DISEASES |
JP5072128B2 (ja) * | 2011-03-31 | 2012-11-14 | 株式会社ワコール | カップ部を有する衣類 |
WO2013022882A1 (fr) | 2011-08-08 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Polythérapie pour le traitement de maladie inflammatoire de démyélinisation |
US9421273B2 (en) * | 2011-12-16 | 2016-08-23 | Biogen Ma Inc. | Silicon-containing fumaric acid esters |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US20130216615A1 (en) | 2012-02-07 | 2013-08-22 | David Goldman | Pharmaceutical Compositions Containing Dimethyl Fumarate |
WO2014031901A1 (fr) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Procédés d'utilisation de fumarate de monométhyle et promédicaments correspondants |
TW201436790A (zh) | 2012-12-21 | 2014-10-01 | Biogen Idec Inc | 經氘取代之反丁烯二酸酯衍生物類 |
EP3243511B1 (fr) | 2012-12-21 | 2019-03-20 | ratiopharm GmbH | Promédicaments de monométhylfumarate (mmf) |
AU2014205529B2 (en) | 2013-01-08 | 2018-08-09 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
WO2015042294A1 (fr) * | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Compositions de nanoparticules de fumarate de diméthyle |
CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
WO2016074684A1 (fr) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Dérivés d'acide fumarique à usage médical |
-
2016
- 2016-03-17 MA MA041785A patent/MA41785A/fr unknown
- 2016-03-18 EP EP16715662.9A patent/EP3270895A2/fr not_active Withdrawn
- 2016-03-18 AR ARP160100749A patent/AR104029A1/es unknown
- 2016-03-18 JP JP2017549232A patent/JP2018508559A/ja not_active Withdrawn
- 2016-03-18 CA CA2979544A patent/CA2979544A1/fr not_active Abandoned
- 2016-03-18 MX MX2017012239A patent/MX2017012239A/es unknown
- 2016-03-18 EA EA201792076A patent/EA201792076A1/ru unknown
- 2016-03-18 WO PCT/US2016/023021 patent/WO2016153957A2/fr active Application Filing
- 2016-03-18 AU AU2016235743A patent/AU2016235743A1/en not_active Withdrawn
- 2016-03-18 KR KR1020177029928A patent/KR20170138437A/ko not_active IP Right Cessation
- 2016-03-18 CN CN201680028617.1A patent/CN107666905A/zh not_active Withdrawn
- 2016-03-18 US US15/559,265 patent/US20180289655A1/en not_active Abandoned
- 2016-03-18 TW TW105108578A patent/TW201642847A/zh unknown
-
2017
- 2017-09-18 IL IL254576A patent/IL254576A0/en unknown
-
2018
- 2018-03-23 HK HK18104073.2A patent/HK1244680A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170138437A (ko) | 2017-12-15 |
AR104029A1 (es) | 2017-06-21 |
HK1244680A1 (zh) | 2018-08-17 |
US20180289655A1 (en) | 2018-10-11 |
JP2018508559A (ja) | 2018-03-29 |
WO2016153957A3 (fr) | 2016-11-10 |
CA2979544A1 (fr) | 2016-09-29 |
EP3270895A2 (fr) | 2018-01-24 |
TW201642847A (zh) | 2016-12-16 |
CN107666905A (zh) | 2018-02-06 |
WO2016153957A2 (fr) | 2016-09-29 |
IL254576A0 (en) | 2017-11-30 |
EA201792076A1 (ru) | 2018-04-30 |
AU2016235743A1 (en) | 2017-10-12 |
MX2017012239A (es) | 2018-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL298689B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
ME03314B (fr) | Thérapie basée sur l'arnm pour le traitement des maladies oculaires | |
EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
EP3389725A4 (fr) | Compositions et méthodes pour le traitement de maladies du système nerveux central | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
EP3340982A4 (fr) | Composés pour le traitement de troubles immunitaires et inflammatoires | |
EP3313402C0 (fr) | Inhibiteurs de vmat2 pour le traitement de maladies ou troubles neurologiques | |
EP2861246A4 (fr) | Compositions et procédés pour l'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de divers troubles et maladies | |
EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
EP3429605A4 (fr) | Agent thérapeutique pour le traitement de maladies, notamment les maladies touchant le système nerveux central | |
EP3390642A4 (fr) | Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13 | |
EP2983791A4 (fr) | Procédés et compositions pour le traitement de maladies auto-immunes | |
EP2967062A4 (fr) | Déséthylhydroxychloroquine pour le traitement de maladies associées avec l'inflammation | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
EP3443962A4 (fr) | Dérivé de quinoline pour le traitement du cancer de l'estomac | |
EP3481958A4 (fr) | Procédés et compositions de traitement de troubles et de maladies impliquant rdh12 | |
EP3370725A4 (fr) | Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2 | |
ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
EP3358929A4 (fr) | Procédés et appareils pour le traitement d'une matière agricole | |
EP3347010A4 (fr) | Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer | |
EP2962693A4 (fr) | Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer | |
EP3389673A4 (fr) | Procédés et compositions pour l'administration de polynucléotides | |
EP3302529A4 (fr) | Compositions et procédés pour le traitement de l'atrésie des voies biliaires néonatale |